Compare Recursion Pharmaceuticals Inc (RXRX) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs AT&T Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $4.27 (market cap $2.14B), while AT&T Inc. trades at $22.16 (market cap $170.42B). The key difference: AT&T Inc. is far larger — about 79.6× Recursion Pharmaceuticals Inc's market cap, and AT&T Inc. pays a 4.46% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and AT&T Inc. for 118 Days on average.
| RXRX | T | |
|---|---|---|
Market Cap | $2.14B | $170.42B |
Volume | 30,789,535 | 50,780,036 |
Sector | Health | Media |
52-Week High | $6.79 | $29.10 |
52-Week Low | $2.84 | $20.49 |
Typical Hold Time | 22 Days | 118 Days |
Enterprise Value | $1.66B | $315.74B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
AT&T (T) trades at $22.105, down 9.68% in the last session, reflecting market concerns despite strong fundamentals. The stock shows solid profitability with 16.94% net margin and attractive valuation at 8.21 P/E. Recent earnings beats and a $3 billion fiber deal with Corning highlight growth initiatives, while technical indicators show mixed signals with RSI at neutral levels.
The outlook remains balanced with analyst consensus at $27.50 target suggesting 24% upside, supported by fiber expansion and wireless growth. Key risks include heavy debt load at $118.44 billion and competitive pressures. The 4% dividend yield provides income support, but investors should monitor execution on debt reduction and revenue trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
